Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21:17:2397-2419.
doi: 10.2147/NDT.S312966. eCollection 2021.

Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review

Shimaa Aboelbaha  1 , Monica Zolezzi  2 , Hazem Elewa  2
Affiliations
Review

Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review

Shimaa Aboelbaha et al. Neuropsychiatr Dis Treat. .

Abstract

Objective: Evidence supporting the utility of pharmacogenetic (PGX) tests in depression is scarce. The main objectives of this study were to summarize, update, and assess the quality of the available evidence regarding PGX testing in depression as well as estimating the impact of using PGX testing tools in depression outcomes in the Middle East/North Africa (MENA) region.

Methodology: Scientific databases were systematically searched from inception to June 30, 2020 for systematic reviews and randomized controlled trials (RCTs) assessing the clinical utility of PGX tests in the treatment of depression. Meta-analyses only and RCTs that were included in eligible systematic reviews were excluded. The quality of the eligible studies was assessed using the Crowe Critical Appraisal Tool (CCAT).

Results: Six systematic reviews and three RCTs met the inclusion criteria and were included in this study. The results of the systematic reviews provided weak evidence on the efficacy of PGX testing, especially in patients with moderate-severe depression at 8 weeks. In addition, there was a lack of evidence regarding safety outcomes. Newer RCTs with better quality showed clinical promise regarding efficacy outcomes, especially in patients with gene-drug interactions. No evidence was found regarding PGX testing impact in the MENA region.

Conclusion: This systematic review is an update and summary of the available literature on the clinical utility of PGX testing in depression. The findings of this study demonstrate that PGX testing prior to treatment initiation or during the course of therapy may improve efficacy outcomes. Further studies are warranted to assess the impact of PGX testing on safety outcomes.

Keywords: antidepressant treatment response; clinical decision support; major depressive disorder; pharmacogenetic testing.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow diagram of selection process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. Depression. Who.int. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed October6, 2019.
    1. Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–493. - PMC - PubMed
    1. König H, König H, Konnopka A. The excess costs of depression: a systematic review and meta-analysis. Epidemiol Psychiatr Sci. 2019;29. - PMC - PubMed
    1. National Institute for Health and Care Excellence. Depression in Adults: Recognition and Management. London: NICE; 2009. Available fromhttps://www.nice.org.uk/guidance/cg90. Accessed October6, 2019. - PubMed
    1. Treatment Guidelines: Depression. CPNP. 2021. Available from: https://cpnp.org/guideline/external/depression. Accessed February21, 2021.